文献速递呼吸道感染呼吸危重症与机械通气

COVID-19相关ARDS患者存在两种转录组聚类:免疫特征与结局不同

Identification of two specific transcriptomic clusters of COVID-19 acute respiratory distress syndrome patients with different immune profiles and different outcomes.
PubMed 文献 · Eur Respir J · 2023-01-27

该研究对COVID-19所致ARDS患者进行转录组聚类分析,识别出两种具有不同免疫特征和不同结局的特定转录组聚类。这证明了COVID-19 ARDS患者间存在异质性,可能有助于建立个体化治疗。

要点

  • COVID-19相关ARDS患者可基于转录组聚类分为两种免疫特征不同的亚型。
  • 不同转录组聚类对应不同临床结局,体现患者异质性。
  • 该分型可能为个体化治疗策略提供依据。

核心结论

  • COVID-19相关ARDS患者存在两种特定转录组聚类,免疫特征与结局不同。

主要发现

  • 转录组聚类分析识别出两种免疫特征不同的COVID-19 ARDS患者聚类。
  • 不同聚类对应不同结局,提示患者间存在异质性。

临床怎么用

  • 可考虑基于转录组聚类对COVID-19 ARDS患者进行分型以指导个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transcriptomic clustering of patients with ARDS due to COVID-19 identified different immune profiles and outcomes. This demonstrates heterogeneity among COVID-19 ARDS patients and may help to establish personalised therapies. https://bit.ly/3h61sCj Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the respiratory illness COVID-19 (coronavirus disease 2019). The virus was first identified in December 2019 in Wuhan, China and has since then spread globally, resulting in the ongoing SARS-CoV-2 pandemic, causing more than 615 million confirmed cases of infection (https://covid19.who.int/). Although the largest proportion of SARS-CoV-2 infections in humans is characterised by a mild course of disease, about 5% to 20% of patients are hospitalised with COVID-19 due to a more severe course of disease, and require admission to the intensive care unit for diffuse lung infiltrates and severe hypoxaemia [1].

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Shindo Y, Dela Cruz CS, Witzenrath M, et al. Identification of two specific transcriptomic clusters of COVID-19 acute respiratory distress syndrome patients with different immune profiles and different outcomes. Eur Respir J. 2023. PMID: 36517181. doi:10.1183/13993003.02008-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。